Colin D. Weekes

15.6k total citations · 3 hit papers
144 papers, 3.5k citations indexed

About

Colin D. Weekes is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Colin D. Weekes has authored 144 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 112 papers in Oncology, 41 papers in Pulmonary and Respiratory Medicine and 40 papers in Cancer Research. Recurrent topics in Colin D. Weekes's work include Pancreatic and Hepatic Oncology Research (67 papers), Cancer Genomics and Diagnostics (35 papers) and Colorectal Cancer Treatments and Studies (18 papers). Colin D. Weekes is often cited by papers focused on Pancreatic and Hepatic Oncology Research (67 papers), Cancer Genomics and Diagnostics (35 papers) and Colorectal Cancer Treatments and Studies (18 papers). Colin D. Weekes collaborates with scholars based in United States, Germany and Spain. Colin D. Weekes's co-authors include Wells A. Messersmith, Sabine Eckhardt, Stephen Leong, John J. Arcaroli, Todd M. Pitts, Antonio Jimeno, Aik Choon Tan, John J. Tentler, Anirban Maitra and William L. Hwang and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Colin D. Weekes

137 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Patient-derived tumour xenografts as models for oncology drug development

2012 933 citations Aik Choon Tan, Colin D. Weekes et al. profile →
Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma

2020 318 citations Colin D. Weekes et al. profile →
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial

2024 124 citations Shubham Pant, Zev A. Wainberg et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Colin D. Weekes United States	28	2.1k	1.4k	758	634	379	144	3.5k
Paul Frankel United States	34	1.9k 0.9×	1.8k 1.3×	658 0.9×	967 1.5×	388 1.0×	214	4.1k
Ignacio Garrido‐Laguna United States	32	3.1k 1.4×	1.8k 1.3×	1.5k 1.9×	1.1k 1.7×	493 1.3×	160	4.9k
Adrian M. Jubb United Kingdom	32	1.6k 0.8×	2.5k 1.8×	1.0k 1.3×	630 1.0×	351 0.9×	50	4.0k
George N. Naumov United States	22	2.3k 1.1×	1.9k 1.4×	1.1k 1.5×	1.3k 2.1×	254 0.7×	37	4.0k
Paolo Michieli Italy	28	1.8k 0.9×	2.7k 2.0×	1.1k 1.4×	503 0.8×	355 0.9×	41	4.6k
N.V. Rajeshkumar United States	29	2.8k 1.3×	1.9k 1.4×	1.3k 1.8×	480 0.8×	398 1.1×	43	4.3k
Giulio Francia United States	31	1.5k 0.7×	1.5k 1.1×	849 1.1×	540 0.9×	346 0.9×	69	3.2k
Karin A. Oien United Kingdom	31	2.1k 1.0×	1.1k 0.8×	834 1.1×	496 0.8×	258 0.7×	64	3.6k
Oddbjørn Straume Norway	31	2.4k 1.1×	2.8k 2.0×	1.3k 1.7×	694 1.1×	495 1.3×	69	4.6k

Countries citing papers authored by Colin D. Weekes

Since Specialization

Citations

This map shows the geographic impact of Colin D. Weekes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Colin D. Weekes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Colin D. Weekes more than expected).

Fields of papers citing papers by Colin D. Weekes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Colin D. Weekes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Colin D. Weekes. The network helps show where Colin D. Weekes may publish in the future.

Co-authorship network of co-authors of Colin D. Weekes

This figure shows the co-authorship network connecting the top 25 collaborators of Colin D. Weekes. A scholar is included among the top collaborators of Colin D. Weekes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Colin D. Weekes. Colin D. Weekes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wainberg, Zev A., Colin D. Weekes, Muhammad Furqan, et al.. (2025). Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results. Nature Medicine. 31(11). 3648–3653. 7 indexed citations

Cohen, Deirdre Jill, Judith D. Goldberg, Lawrence P. Leichman, et al.. (2024). Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial.. Journal of Clinical Oncology. 42(16_suppl). 4175–4175. 1 indexed citations

Pant, Shubham, Zev A. Wainberg, Colin D. Weekes, et al.. (2024). Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nature Medicine. 30(2). 531–542. 124 indexed citations breakdown →

Coté, Gregory M., Bose Kochupurakkal, T. Khanh, et al.. (2024). A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors. Clinical Cancer Research. 31(1). 35–44. 4 indexed citations

Pathak, Priyadarshini, Colin D. Weekes, & Jennifer Y. Wo. (2024). Small steps can lead to substantial breakthroughs: moving the therapeutic needle forward in pancreatic cancer. The Lancet Oncology. 25(7). 824–825. 2 indexed citations

Roberts, Hannah, Beow Y. Yeap, Julie L. Koenig, et al.. (2024). SBRT with ipilimumab and nivolumab to metastatic MSS colorectal and pancreatic cancer: A pooled analysis of four prospective phase II trials.. Journal of Clinical Oncology. 42(3_suppl). 752–752.

Corcoran, Ryan B., T. Khanh, James M. Cleary, et al.. (2023). 664P Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors. Annals of Oncology. 34. S467–S467. 1 indexed citations

Yu, Kenneth H., et al.. (2023). The SHARON trial: A study of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cell rescue for metastatic pancreatic cancer with an inherited BRCA mutation.. Journal of Clinical Oncology. 41(4_suppl). TPS774–TPS774.

Weekes, Colin D., David T. Ting, Aparna R. Parikh, et al.. (2023). Phase Ib study testing neoadjuvant transforming growth factor (TGF)-β antibody, NIS793, plus 5-fluorouracil, irinotecan, and oxaliplatin chemotherapy (FOLFIRINOX) in patients (pts) with borderline resectable (BR)/locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology. 41(4_suppl). TPS762–TPS762. 1 indexed citations

10.

Tolaney, Sara M., T. Khanh, Joseph P. Eder, et al.. (2020). A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors. Clinical Cancer Research. 26(21). 5588–5597. 15 indexed citations

11.

Strickler, John H., Colin D. Weekes, John Nemunaitis, et al.. (2018). First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 36(33). 3298–3306. 104 indexed citations

12.

Le, Dung T., Andrew H. Ko, Zev A. Wainberg, et al.. (2017). Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study).. Journal of Clinical Oncology. 35(4_suppl). 345–345. 39 indexed citations

13.

Modi, Shanu, Joseph P. Eder, Patricia LoRusso, et al.. (2016). A phase I study evaluating DLYE5953A, an antibody-drug conjugate targeting the tumor-associated antigen lymphocyte antigen 6 complex locus E (Ly6E), in patients (Pts) with solid tumors. Annals of Oncology. 27. vi114–vi114.

14.

Weekes, Colin D., Heinz‐Josef Lenz, Bert H. O’Neil, et al.. (2016). Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC). Annals of Oncology. 27. vi117–vi117. 12 indexed citations

15.

Teneggi, Vincenzo, Matthew Ng, David S.P. Tan, et al.. (2016). 152O A phase 1, first-in-human dose escalation study of ETC-159 in advanced or metastatic solid tumours. Annals of Oncology. 27. ix47–ix47. 10 indexed citations

16.

Bowles, Daniel W., Jennifer R. Diamond, Elaine T. Lam, et al.. (2014). Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies. Clinical Cancer Research. 20(6). 1656–1665. 54 indexed citations

17.

Weekes, Colin D., Daniel D. Von Hoff, Alex A. Adjei, et al.. (2013). Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer. Clinical Cancer Research. 19(5). 1232–1243. 46 indexed citations

18.

Wee, Wen, Wells A. Messersmith, Grace K. Dy, et al.. (2012). Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer. Clinical Cancer Research. 18(7). 2048–2055. 42 indexed citations

19.

Yan, Xin, Jessica Li, Jenny Wu, et al.. (2012). Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(21). 6040–6048. 33 indexed citations

20.

Sharp, John, et al.. (1995). Culture Methods for the Detection of Minimal Tumor Contamination of Hematopoietic Harvests: A Review. Journal of Hematotherapy. 4(3). 141–148. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact